Inclusion Criteria:  Study participants must meet all of the following inclusion criteria to participate in the study:  Adult female study participants (≥18 years) with newly diagnosed early-stage (stages I III) non-metastatic breast cancer receiving neoadjuvant or adjuvant chemotherapy that includes paclitaxel or docetaxel Study participants must be capable and willing to provide informed consent, and be willing and able to complete the study questionnaires during the study  Exclusion Criteria:  Study participants who fulfill any of the following criteria will be excluded:  Patients with metastatic breast cancer History of other cancers (except squamous and basal cell carcinoma) Autoimmune disorders Presence of major active infection for which antibiotics and/or antivirals are prescribed within the last 14 days (chronic or acute, eg, sepsis, HIV, pneumonia, active COVID infection) Pregnant women Participation in an additional study at the time of enrollment where the intervention could potentially alter CIPN risk (unless in the control arm)